Changes in Posttreatment Spleen Volume Associated with Immunotherapy Outcomes for Advanced Hepatocellular Carcinoma.

Bang-Bin ChenPo-Chin LiangTiffany Ting-Fang Shih Tsung-Hao LiuYing-Chun ShenLi-Chun LuZhong-Zhe LinChiun HsuChih-Hung HsuAnn-Lii ChengYu-Yun Shao

Published in: Journal of hepatocellular carcinoma (2024)

Most patients exhibited an increase in SV after the initiation of immunotherapy, which may be used to predict response and prognosis. However, this association was not observed in patients who received sorafenib.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
skeletal muscle
adipose tissue
metabolic syndrome
insulin resistance